Fulgent Genetics Q4 revenue misses; forecasts about $350 mln in 2026 revenue
FLGT sits 61% above its 52-week low of $14.57 on elevated volume (3.0× avg).
Summary
Fulgent Genetics reported Q4 revenue of $83.34 million, missing analyst expectations of $85.38 million, and an adjusted EBITDA loss of $4.50 million, also below consensus. For 2026, the company provided guidance of approximately $350 million in revenue and a non-GAAP loss of about ($1.45) per share. While Q4 results were partially covered by an earlier report, the detailed 2026 guidance is new and material. The misses on Q4 results combined with a forecast for continued losses in 2026 present a negative outlook, likely impacting investor sentiment and potentially leading to downward pressure on the stock. Traders will monitor the company's ability to execute on its 2026 revenue targets and improve profitability.
At the time of this announcement, FLGT was trading at $23.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $765.4M. The 52-week trading range was $14.57 to $31.04. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.